Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events

Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events

Immune checkpoint inhibitors (ICIs) affect immunologic homeostasis, leading to immune-related adverse events (irAEs). Early irAE detection and management can prevent significant morbidity and mortality. A retrospective chart review was performed to characterize irAEs associated with nivolumab, ipili...

Full description

Bibliographic Details
Main Authors:	Arezou Teimouri, Laura V. Minard, Samantha N. Scott, Amanda Daniels, Stephanie Snow
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Series:	Current Oncology
Subjects:	immune-related adverse events immune checkpoint inhibitors quality assurance toxicity guideline adherence
Online Access:	https://www.mdpi.com/1718-7729/29/5/252

Similar Items

Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus
by: Min Shen, et al.
Published: (2023-07-01)

Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management
by: Zoe Apalla, PhD, et al.
Published: (2021-12-01)

Overview and management of toxicities of immune checkpoint-blocking drugs
by: Economopoulou Panagiota, et al.
Published: (2016-03-01)

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations
by: Benjamin C. Park, et al.
Published: (2023-12-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
by: Yue Li, et al.
Published: (2020-04-01)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
by: I. Puzanov, et al.
Published: (2017-11-01)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
by: Xiaoyan Si, et al.
Published: (2020-03-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors
by: Yue LI, et al.
Published: (2019-10-01)

Rheumatological Adverse Events Following Immunotherapy for Cancer
by: Ioana Cretu, et al.
Published: (2022-01-01)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
by: Bianca Gautron Moura, et al.
Published: (2022-12-01)

Updated Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors - edition 2.0
by: Rodrigo Ramella Munhoz, et al.
Published: (2022-10-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
by: Xiaoyan Si, et al.
Published: (2020-02-01)

An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis
by: Kai-li Liang, et al.
Published: (2022-06-01)

Imaging assessment of toxicity related to immune checkpoint inhibitors
by: Antonia M. Berz, et al.
Published: (2023-02-01)

A multicenter retrospective analysis: Factors influencing hepatic adverse events induced by immunotherapy in advanced liver cancer
by: Rui Zou, et al.
Published: (2024-02-01)

Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
by: Yoko Maegawa, et al.
Published: (2020-09-01)

Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy
by: Terufumi Kubo, et al.
Published: (2021-09-01)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
by: Junling Zhuang, et al.
Published: (2020-03-01)

Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events
by: Junling ZHUANG, et al.
Published: (2019-10-01)

IMMUNE CHECKPOINT INHIBITORS AND RHEUMATIC ADVERSE EVENTS
by: Ioana Cretu, et al.
Published: (2018-12-01)

Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors
by: LI Ying, et al.
Published: (2021-04-01)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
by: Hanna Karhapää, et al.
Published: (2022-02-01)

Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews
by: WANG Xue, et al.
Published: (2020-06-01)

Short review of immunotherapy toxicity
by: Ivana Canjko, et al.
Published: (2021-01-01)

Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review
by: Marion Allouchery, et al.
Published: (2022-02-01)

Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines
by: Saralinh Trinh, et al.
Published: (2019-01-01)

Research hot spots and trends in endocrine-related adverse events caused by immune checkpoint inhibitors: a bibliometric analysis and visualization research
by: Jun Zhao, et al.
Published: (2024-04-01)

Rheumatic Immune-related Adverse Events and Treatment of Immune Checkpoint Inhibitors
by: ZHANG Xue, et al.
Published: (2020-11-01)

The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patients’ Outcomes
by: Hamzah Abu-Sbeih, et al.
Published: (2018-07-01)

Baseline risk factors associated with immune related adverse events and atezolizumab
by: Katrin Madjar, et al.
Published: (2023-02-01)

Ocular adverse events associated with immune checkpoint inhibitors, a scoping review
by: A. Martens, et al.
Published: (2023-02-01)

Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences
by: Ana Cardeña-Gutiérrez, et al.
Published: (2022-06-01)

Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
by: Lingli Luo, et al.
Published: (2023-04-01)

Rheumatic Immune-Related Adverse Events—A Consequence of Immune Checkpoint Inhibitor Therapy
by: Anca Bobircă, et al.
Published: (2021-06-01)

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
by: Fan Yang, et al.
Published: (2023-01-01)

Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management
by: Yu-Wen Zhou, et al.
Published: (2022-04-01)

Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors
by: Nicholas Gulati, et al.
Published: (2020-11-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events of Edocrine System Related to Immune Checkpoint Inhibitors
by: Lian DUAN, et al.
Published: (2019-10-01)

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events
by: Peng Song, et al.
Published: (2020-08-01)

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
by: Iñigo Les, et al.
Published: (2023-03-01)